MA50145A - Composés inhibiteurs de vmat2 et compositions de ceux-ci - Google Patents

Composés inhibiteurs de vmat2 et compositions de ceux-ci

Info

Publication number
MA50145A
MA50145A MA050145A MA50145A MA50145A MA 50145 A MA50145 A MA 50145A MA 050145 A MA050145 A MA 050145A MA 50145 A MA50145 A MA 50145A MA 50145 A MA50145 A MA 50145A
Authority
MA
Morocco
Prior art keywords
compositions
inhibitor compounds
vmat2 inhibitor
vmat2
compounds
Prior art date
Application number
MA050145A
Other languages
English (en)
French (fr)
Inventor
Shawn Branum
Jeffrey C Culhane
Nicole Harriott
Donald Hettinger
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MA50145A publication Critical patent/MA50145A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA050145A 2017-04-19 2018-04-17 Composés inhibiteurs de vmat2 et compositions de ceux-ci MA50145A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US201862652837P 2018-04-04 2018-04-04

Publications (1)

Publication Number Publication Date
MA50145A true MA50145A (fr) 2020-07-29

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050145A MA50145A (fr) 2017-04-19 2018-04-17 Composés inhibiteurs de vmat2 et compositions de ceux-ci

Country Status (17)

Country Link
US (1) US11040970B2 (https=)
EP (1) EP3612532B1 (https=)
JP (1) JP7170662B2 (https=)
KR (1) KR20190140968A (https=)
CN (1) CN110770236B (https=)
AU (1) AU2018254429A1 (https=)
BR (1) BR112019021853A2 (https=)
CA (1) CA3060251A1 (https=)
CL (1) CL2019002919A1 (https=)
CO (1) CO2019011604A2 (https=)
ES (1) ES2971230T3 (https=)
JO (1) JOP20190239A1 (https=)
MA (1) MA50145A (https=)
MX (1) MX2019012336A (https=)
PE (1) PE20191784A1 (https=)
TW (1) TW201841913A (https=)
WO (1) WO2018195121A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 特定のvmat2インヒビターを投与するための方法
MX2020013004A (es) * 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020086765A1 (en) * 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
PT4168409T (pt) 2021-03-22 2025-06-12 Neurocrine Biosciences Inc Inibidores de vmat2 e métodos de utilização
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
US20250064990A1 (en) 2021-08-20 2025-02-27 Neurocrine Biosciences, Inc. Methods of screening for vmat2 inhibitors
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
RU2339636C2 (ru) 2003-06-20 2008-11-27 Ф.Хоффманн-Ля Рош Аг Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv)
AU2005272773A1 (en) 2004-08-13 2006-02-23 Omeros Corporation Novel serotonin receptor ligands and their uses thereof
PL2081929T3 (pl) 2006-11-08 2013-06-28 Neurocrine Biosciences Inc Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
FR2912145B1 (fr) 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2009126305A1 (en) 2008-04-11 2009-10-15 The Trustees Of Columbia University Glucose metabolism modulating compounds
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2784830C (en) 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984B (zh) 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2014043866A1 (zh) 2012-09-19 2014-03-27 中国科学院福建物质结构研究所 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途
NZ760790A (en) 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
CA2974540C (en) * 2015-02-06 2023-09-26 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
EP3558990B1 (en) 2016-12-22 2022-08-10 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators

Also Published As

Publication number Publication date
CL2019002919A1 (es) 2020-01-17
KR20190140968A (ko) 2019-12-20
US20200131173A1 (en) 2020-04-30
JP7170662B2 (ja) 2022-11-14
TW201841913A (zh) 2018-12-01
CA3060251A1 (en) 2018-10-25
MX2019012336A (es) 2020-07-14
JP2020517607A (ja) 2020-06-18
WO2018195121A1 (en) 2018-10-25
CO2019011604A2 (es) 2019-10-31
EP3612532A1 (en) 2020-02-26
PE20191784A1 (es) 2019-12-24
CN110770236B (zh) 2023-03-24
BR112019021853A2 (pt) 2020-05-26
JOP20190239A1 (ar) 2019-10-09
CN110770236A (zh) 2020-02-07
EP3612532C0 (en) 2023-12-13
EP3612532B1 (en) 2023-12-13
AU2018254429A1 (en) 2019-11-07
US11040970B2 (en) 2021-06-22
ES2971230T3 (es) 2024-06-04

Similar Documents

Publication Publication Date Title
MA50145A (fr) Composés inhibiteurs de vmat2 et compositions de ceux-ci
EP3897522A4 (en) MICROCAPSULE COMPOSITION
PL3510033T3 (pl) Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych
IL263586B (en) Inhibitors of the menin-mll interaction
HUE060078T2 (hu) CDK7 gátlására alkalmas vegyületek
MA41677A (fr) Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
MA55633A (fr) Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock
MA46242A (fr) Composés inhibiteurs de bêta-lactamase
EP3700934A4 (en) COMPOUNDS AND USES THEREOF
MA52896A (fr) Composés inhibiteurs de vmat2, compositions et méthodes associées
EP3681499A4 (en) CONNECTIONS AS RAS INHIBITORS AND THEIR USE
EP3317241A4 (en) THERAPEUTIC INHIBITING COMPOUNDS
DK3143026T3 (da) Forbindelser og sammensætninger til induktion af chondrogenese
EP3842425A4 (en) NOVEL QUINOLINE DERIVATIVE INHIBITORS
MA54143A (fr) Compositions et méthodes
EP3908319A4 (en) Metalloenzyme inhibitor compounds
EP3556758A4 (en) CDK4 / 6-INHIBITOR
EP3810118A4 (en) FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDS
EP3917910A4 (en) THERAPEUTIC COMPOUNDS AND COMPOSITIONS
PL4073164T3 (pl) Związki trójamidowe i kompozycje je zawierające
EP3310794A4 (en) Synthesis and Application of Microbial Compounds
IL264445A (en) Compounds and compositions and uses thereof
DK3678644T3 (da) Formuleringer af copanlisib
EP3661505A4 (en) BENZOTHIAZOLE AND RELATED COMPOUNDS
EP3897615A4 (en) CANNABIS COMPOSITIONS AND METHODS